The effect of pharmacological cessation and restoration of menstrual cycle on bone metabolism in premenopausal women with endometriosis

被引:3
作者
Anastasilakis, Athanasios D. [1 ]
Papachatzopoulos, Stergios [2 ]
Makras, Polyzois [3 ]
Gkiomisi, Athina [2 ]
Nikolakopoulos, Panagiotis [2 ]
Polyzos, Stergios A. [4 ]
Ntenti, Charikleia [4 ]
Ballaouri, Iris [5 ]
Gerou, Spyridon [5 ]
Tsachouridou, Olga [6 ]
Papatheodorou, Athanasios [3 ]
Aliazis, Konstantinos [3 ]
Fermanoglou, Sofia [7 ]
Bisbinas, Ilias [8 ]
Yavropoulou, Maria P. [9 ]
机构
[1] 424 Gen Mil Hosp, Dept Endocrinol, Thessaloniki, Greece
[2] 424 Gen Mil Hosp, Dept Obstet & Gynaecol, Thessaloniki, Greece
[3] 251 Hellen Air Force & VA Gen Hosp, Dept Endocrinol & Diabet, Dept Med Res, Athens, Greece
[4] Aristotle Univ Thessaloniki, Sch Med, Lab Pharmacol 1, Thessaloniki, Greece
[5] Anal Labs, Thessaloniki, Greece
[6] AHEPA Hosp, Dept Internal Med 1, Thessaloniki, Greece
[7] 424 Gen Mil Hosp, Dept Orthopaed 1, Thessaloniki, Greece
[8] AHEPA Hosp, Dept Clin Densitometry, Thessaloniki, Greece
[9] Natl & Kapodistrian Univ Athens, Med Sch, Dept Propaedeut & Internal Med 1, Endocrinol Unit, Athens, Greece
关键词
Menstrual cessation; GnRH analog; Bone mineral density; Bone turnover markers; Sclerostin; Circulating miRNA; HORMONE AGONIST THERAPY; MINERAL DENSITY; GNRH AGONIST; SYMPTOMATIC ENDOMETRIOSIS; OSTEOBLAST DIFFERENTIATION; POSTMENOPAUSAL WOMEN; ESTROGEN DEFICIENCY; OVARIAN SUPPRESSION; SCLEROSTIN LEVELS; NAFARELIN;
D O I
10.1016/j.bone.2022.116354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: GnRH-analogs induce bone loss. We aimed to investigate the effects of goserelin-induced menstrual cessation (MC) and subsequent menstrual restoration (MR) on bone metabolism (BM). Methods: In this prospective cohort study, premenopausal women (PMW) with histologically verified endometriosis (n = 21) received goserelin monthly for 6 months (6 m) resulting in MC and were followed up for another 6 m after MR (12 m). Age- and BMI-matched healthy PMW (n = 20) served as controls for bone mineral density (BMD) measurements. The primary endpoint was changes in lumbar spine (LS)-BMD at 6 m and 12 m; Secondary endpoints were changes in femoral neck (FN)-BMD, bone turnover markers (P1NP and CTx), sclerostin, and expression of bone-related circulating microRNAs (miRNAs) at 6 m and 12 m. Results: Goserelin-induced MC reduced LS- and FN-BMD at 6 m (both p < 0.001). From 6 m to 12 m, LS-BMD increased (p < 0.001) but remained below baseline values (p = 0.012), whereas FN-BMD remained stable (p = 1.000). CTx and P1NP levels increased at 6 m (both p < 0.001) and decreased at 12 m (p < 0.001 and p = 0.013, respectively), while CTx (p = 1.000) alone and not P1NP (p = 0.020) returned to baseline. Sclerostin levels did not change. Relative expression of miRNAs targeting RUNX 2 and beta-catenin was significantly downregulated at 6 m compared to baseline (p < 0.001), while the expression of miRNAs targeting osteoblast and osteoclast function at both directions demonstrated a robust increase (up to 400fold) at 12 m (p < 0.001). Conclusions: Six months of goserelin-induced MC lead to significant bone loss associated with increased bone turnover and changes in the expression of bone-related miRNAs, changes that are only partially reversed at 6 m after MR.
引用
收藏
页数:9
相关论文
共 63 条
[1]   Therapeutic efficacy and bone mineral density response during and following a three-month re-treatment of endometriosis with nafarelin (Synarel) [J].
Adamson, GD ;
Heinrichs, WL ;
Henzl, MR ;
Yuzpe, AA ;
Berquist, C ;
Jacobson, JJ ;
Eriksson, S ;
Kwei, L ;
Gilbert, SM .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1997, 177 (06) :1413-1418
[2]   LONG-TERM GONADOTROPIN-RELEASING-HORMONE AGONIST THERAPY - THE EVOLVING ISSUE OF STEROIDAL ADD-BACK PARADIGMS [J].
ADASHI, EY .
HUMAN REPRODUCTION, 1994, 9 (07) :1380-1397
[3]  
Agarwal SK, 2002, J REPROD MED, V47, P530
[4]   Changes of Circulating MicroRNAs in Response to Treatment With Teriparatide or Denosumab in Postmenopausal Osteoporosis [J].
Anastasilakis, Athanasios D. ;
Makras, Polyzois ;
Pikilidou, Maria ;
Tournis, Symeon ;
Makris, Konstantinos ;
Bisbinas, Ilias ;
Tsave, Olga ;
Yovos, John G. ;
Yavropoulou, Maria P. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (03) :1206-1213
[5]  
Andreyko J L, 1987, Obstet Gynecol Surv, V42, P1
[6]   miR-208a-3p Suppresses Osteoblast Differentiation and Inhibits Bone Formation by Targeting ACVR1 [J].
Arfat, Yasir ;
Basra, Muhammad Asim R. ;
Shahzad, Muhammad ;
Majeed, Kashif ;
Mahmood, Nasir ;
Munir, Hina .
MOLECULAR THERAPY-NUCLEIC ACIDS, 2018, 11 :323-336
[7]   EFFECTS ON BONE-MINERAL DENSITY OF 12-MONTH GOSERELIN TREATMENT IN OVER 40-YEAR-OLD WOMEN WITH UTERINE MYOMAS [J].
BIANCHI, S ;
FEDELE, L ;
VIGNALI, M ;
GALBIATI, E ;
CHERUBINI, R ;
ORTOLANI, S .
CALCIFIED TISSUE INTERNATIONAL, 1995, 57 (01) :78-80
[8]   Biochemical markers as predictors of bone mineral density changes after GnRH agonist treatment [J].
Borderie, D ;
Cherruau, B ;
Dougados, M ;
Ekindjian, OG ;
Roux, C .
CALCIFIED TISSUE INTERNATIONAL, 1998, 62 (01) :21-25
[9]   MiR-503 Regulates Osteoclastogenesis via Targeting RANK [J].
Chen, Chao ;
Cheng, Peng ;
Xie, Hui ;
Zhou, Hou-De ;
Wu, Xian-Ping ;
Liao, Er-Yuan ;
Luo, Xiang-Hang .
JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 (02) :338-347
[10]   THE EFFECTS OF GONADOTROPIN-RELEASING-HORMONE AGONISTS ON ILIAC CREST CANCELLOUS BONE-STRUCTURE IN WOMEN WITH ENDOMETRIOSIS [J].
COMPSTON, JE ;
YAMAGUCHI, K ;
CROUCHER, PI ;
GARRAHAN, NJ ;
LINDSAY, PC ;
SHAW, RW .
BONE, 1995, 16 (02) :261-267